| 2018-SELE-68251 | |
| Researchers at Purdue University developed a repurposed drug as a potent inhibitor of Clostridium difficile. Clostridium difficile is the most common and costly healthcare-associated infection with an estimated half a million cases and approximately 29,000 deaths occurring annually in the United States. The rate of death associated with Clostridium difficile infection (CDI) is rising, and the infection is occurring in populations previously considered to be at low risk. Treatment with the standard of care falls short; after treatment, patients' intestines become colonized by vancomycin-resistant enterococci (VRE). The repurposed drug is capable of killing hypervirulent strains of C. diff, suppressing C. diff spore formation, preventing VRE colonization, and avoiding absorption from the intestine. The drug is approved for its original indication outside of the US for oral consumption and in the US for topical application. Advantages: -Kills Clostridium difficile -Suppresses Clostridium difficile spore formation -Reduces vancomycin-resistant enterococci colonization Potential Applications: -Treatment of Clostridium difficile infection |
|
|
|
|
Oct 6, 2020
Utility-Gov. Funding
United States
11,806,342
Nov 7, 2023
Nov 6, 2023
DIV-Gov. Funding
United States
(None)
(None)
Oct 7, 2019
Provisional-Patent
United States
(None)
(None)
Oct 9, 2018
Provisional-Patent
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
